Co-Diagnostics Approves Reverse Stock Split to Maintain Listing

Co-Diagnostics ( (CODX) ) just unveiled an update.

On December 5, 2025, Co-Diagnostics’ stockholders approved a reverse stock split authorization, and on December 29, 2025, the board set the ratio at 1-for-30, combining every 30 issued and outstanding common shares into a single share without changing the par value or shareholder rights. The reverse split becomes effective around midnight leading into January 2, 2026, when the stock will begin trading on a split-adjusted basis on Nasdaq under the existing ticker “CODX” but with a new CUSIP, reducing the company’s outstanding common shares to roughly 2.1 million, proportionally adjusting options and warrants, and rounding any fractional entitlements up to the nearest whole share. The company stated that the move is intended to restore compliance with Nasdaq’s $1.00 minimum bid price requirement, a step that could help preserve its listing and access to public capital markets, while operational mechanics for shareholders will generally be handled automatically through brokers and its transfer agent, VStock Transfer, LLC.

The most recent analyst rating on (CODX) stock is a Hold with a $0.23 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.

Spark’s Take on CODX Stock

According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.

The score is primarily pressured by weak financial performance (declining revenue, losses, and negative free cash flow) and bearish technical signals (below major moving averages with negative MACD). Valuation is constrained by negative earnings and no dividend support, while the earnings call adds modest offset from cost improvements and strategic growth initiatives that are still early-stage versus current financial strain.

To see Spark’s full report on CODX stock, click here.

More about Co-Diagnostics

Co-Diagnostics, Inc., based in Utah and listed on the Nasdaq Capital Market, is a molecular diagnostics company that develops, manufactures and markets diagnostics technologies using nucleic acid (DNA and RNA) detection and analysis. The company’s proprietary platform underpins molecular diagnostic tests and is also used to design specific assays for its Co-Dx PCR at-home and point-of-care platform, which targets infectious disease and other genetic-marker applications but remains subject to regulatory review and is not yet for sale.

Average Trading Volume: 20,995,063

Technical Sentiment Signal: Sell

Current Market Cap: $14.31M

For detailed information about CODX stock, go to TipRanks’ Stock Analysis page.